|
1
|
Theise ND, Chen CJ and Kew MC: Liver
cancerWorld Cancer Report 2014. Stewart B and Wild C: International
Agency for Research on Cancer; Lyon: pp. 577–593. 2014
|
|
2
|
Chen JG and Zhang SW: Liver cancer
epidemic in China: Past, present and future. Semin Cancer Biol.
21:59–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shiraha H, Yamamoto K and Namba M: Human
hepatocyte carcinogenesis (Review). Int J Oncol. 42:1133–1138.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao Z and Huang J: Recent updates of
genetic and genomic alterations in hepatocellular carcinoma.
Hepatoma Res. 2:31–35. 2016.
|
|
5
|
Evans DG, Sainio M and Baser ME:
Neurofibromatosis type 2. J Med Genet. 37:897–904. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chiasson-MacKenzie C, Morris ZS, Baca Q,
Morris B, Coker JK, Mirchev R, Jensen AE, Carey T, Stott SL, Golan
DE, et al: NF2/Merlin mediates contact-dependent inhibition of EGFR
mobility and internalization via cortical actomyosin. J Cell Biol.
211:391–405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pylkkänen L, Sarlomo-Rikala M, Wessman M,
Hämäläinen E, Sainio M, Husgafvel-Pursiainen K and Carpén O:
Chromosome 22q alterations and expression of the NF2 gene product,
merlin, in gastrointestinal stromal tumors. Hum Pathol. 34:872–879.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Benhamouche S, Curto M, Saotome I, Gladden
AB, Liu CH, Giovannini M and McClatchey AI: Nf2/Merlin controls
progenitor homeostasis and tumorigenesis in the liver. Genes Dev.
24:1718–1730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Drvarov O and Cubero FJ: Neurofibromatosis
type 2/Merlin: Sharpening the myth of prometheus. Hepatology.
53:1767–1770. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kanai Y, Tsuda H, Oda T, Sakamoto M and
Hirohashi S: Analysis of the neurofibromatosis 2 gene in human
breast and hepatocellular carcinomas. Jpn J Clin Oncol. 25:1–4.
1995.PubMed/NCBI
|
|
11
|
Yoo NJ, Park SW and Lee SH: Mutational
analysis of tumour suppressor gene NF2 in common solid cancers and
acute leukaemias. Pathology. 44:29–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang J, Zhao YP, Li Q, Zhang JX, Yan W
and Zhang B: Association of single nucleotide polymorphisms of NBS1
gene with genetic susceptibility to primary liver cancer in a
Chinese Han population. Prog Biochem Biophys. 39:678–686. 2012.
View Article : Google Scholar
|
|
13
|
Wang Y, Hong Y, Li M, Long J, Zhao YP,
Zhang JX, Li Q, You H, Tong WM, Jia JD, et al: Mutation
inactivation of Nijmegen breakage syndrome gene (NBS1) in
hepatocellular carcinoma and intrahepatic cholangiocarcinoma. PLoS
One. 8:e824262013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Li M, Long J, Shi XY, Li Q, Chen
J, Tong WM, Jia JD and Huang J: Clinical significance of increased
expression of Nijmegen breakage syndrome gene (NBS1) in human
primary liver cancer. Hepatol Int. 8:250–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hong Y, Long J, Li H, Chen S, Liu Q, Zhang
B, He X, Wang Y, Li H, Li Y, et al: An analysis of immunoreactive
signatures in early stage hepatocellular carcinoma. EBioMedicine.
2:438–446. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagaishi M, Kim YH, Mittelbronn M,
Giangaspero F, Paulus W, Brokinkel B, Vital A, Tanaka Y, Nakazato
Y, Legras-Lachuer C, et al: Amplification of the STOML3, FREM2, and
LHFP genes is associated with mesenchymal differentiation in
gliosarcoma. Am J Pathol. 180:1816–1823. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lutchman M and Rouleau GA:
Neurofibromatosis type 2: A new mechanism of tumor suppression.
Trends Neurosci. 19:373–377. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Legoix P, Legrand MF, Ollagnon E, Lenoir
G, Thomas G and Zucman-Rossi J: Characterisation of 16 polymorphic
markers in the NF2 gene: Application to hemizygosity detection. Hum
Mutat. 13:290–293. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sadetzki S, Flint-Richter P, Starinsky S,
Novikov I, Lerman Y, Goldman B and Friedman E: Genotyping of
patients with sporadic and radiation-associated meningiomas. Cancer
Epidemiol Biomarkers Prev. 14:969–976. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gutmann DH, Giordano MJ, Fishback AS and
Guha A: Loss of merlin expression in sporadic meningiomas,
ependymomas and schwannomas. Neurology. 49:267–270. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ikeda T, Hashimoto S, Fukushige S, Ohmori
H and Horii A: Comparative genomic hybridization and mutation
analyses of sporadic schwannomas. J Neurooncol. 72:225–230. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lomas J, Bello MJ, Arjona D, Alonso ME,
Martinez-Glez V, Lopez-Marin I, Amiñoso C, de Campos JM, Isla A,
Vaquero J, et al: Genetic and epigenetic alteration of the NF2 gene
in sporadic meningiomas. Genes Chromosomes Cancer. 42:314–319.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Łaniewski-Wołłk M, Gos M, Koziarski A and
Szpecht-Potocka A: Identification of mutations in the NF2 gene in
Polish patients with neurofibromatosis type 2. J Appl Genet.
49:297–300. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Baser ME, Kuramoto L, Joe H, Friedman JM,
Wallace AJ, Gillespie JE, Ramsden RT and Evans DG:
Genotype-phenotype correlations for nervous system tumors in
neurofibromatosis 2: A population-based study. Am J Hum Genet.
75:231–239. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sheikh HA, Tometsko M, Niehouse L, Aldeeb
D, Swalsky P, Finkelstein S, Barnes EL and Hunt JL: Molecular
genotyping of medullary thyroid carcinoma can predict tumor
recurrence. Am J Surg Pathol. 28:101–106. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahronowitz I, Xin W, Kiely R, Sims K,
MacCollin M and Nunes FP: Mutational spectrum of the NF2 gene: A
meta-analysis of 12 years of research and diagnostic laboratory
findings. Hum Mutat. 28:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Evans DG, Huson SM, Donnai D, Neary W,
Blair V, Teare D, Newton V, Strachan T, Ramsden R and Harris R: A
genetic study of type 2 neurofibromatosis in the United Kingdom. I.
Prevalence, mutation rate, fitness, and confirmation of maternal
transmission effect on severity. J Med Genet. 29:841–846. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bretscher A, Edwards K and Fehon RG: ERM
proteins and merlin: Integrators at the cell cortex. Nat Rev Mol
Cell Biol. 3:586–599. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cooper J and Giancotti FG: Molecular
insights into NF2/Merlin tumor suppressor function. FEBS Lett.
588:2743–2752. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pećina-Šlaus N: Merlin, the NF2 gene
product. Pathol Oncol Res. 19:365–373. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morrow KA, Das S, Metge BJ, Ye K, Mulekar
MS, Tucker JA, Samant RS and Shevde LA: Loss of tumor suppressor
Merlin in advanced breast cancer is due to post-translational
regulation. J Biol Chem. 286:40376–40385. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Horiguchi A, Zheng R, Shen R and Nanus DM:
Inactivation of the NF2 tumor suppressor protein merlin in DU145
prostate cancer cells. Prostate. 68:975–984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen Z, Fadiel A and Xia Y: Functional
duality of merlin: A conundrum of proteome complexity. Med
Hypotheses. 67:1095–1098. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Eferl R and Wagner EF: AP-1: A
double-edged sword in tumorigenesis. Nat Rev Cancer. 3:859–868.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang N, Bai H, David KK, Dong J, Zheng Y,
Cai J, Giovannini M, Liu P, Anders RA and Pan D: The Merlin/NF2
tumor suppressor functions through the YAP oncoprotein to regulate
tissue homeostasis in mammals. Dev Cell. 19:27–38. 2010. View Article : Google Scholar : PubMed/NCBI
|
